MAGEA4 expression in bone and soft tissue tumors: its utility as a target for immunotherapy and diagnostic marker combined with NY-ESO-1.

about

MAGEA4 expression in bone and soft tissue tumors: its utility as a target for immunotherapy and diagnostic marker combined with NY-ESO-1.

Item

http://www.wikidata.org/entity/Q54489272

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

MAGEA4 expression in bone and ...... marker combined with NY-ESO-1.

@en

MAGEA4 expression in bone and ...... marker combined with NY-ESO-1.

@nl

type

Item

label

MAGEA4 expression in bone and ...... marker combined with NY-ESO-1.

@en

MAGEA4 expression in bone and ...... marker combined with NY-ESO-1.

@nl

prefLabel

MAGEA4 expression in bone and ...... marker combined with NY-ESO-1.

@en

MAGEA4 expression in bone and ...... marker combined with NY-ESO-1.

@nl

P1476

MAGEA4 expression in bone and ...... marker combined with NY-ESO-1

@en

P2093

Akira Maekawa

http://www.w3.org/2001/XMLSchema#string

Hidetaka Yamamoto

http://www.w3.org/2001/XMLSchema#string

Hirofumi Bekki

http://www.w3.org/2001/XMLSchema#string

Hiroshi Otsuka

http://www.w3.org/2001/XMLSchema#string

Kenichi Kohashi

http://www.w3.org/2001/XMLSchema#string

Kunio Iura

http://www.w3.org/2001/XMLSchema#string

Yoshihiro Matsumoto

http://www.w3.org/2001/XMLSchema#string

Yoshinao Oda

http://www.w3.org/2001/XMLSchema#string

Yuichi Yamada

http://www.w3.org/2001/XMLSchema#string

Yukihide Iwamoto

http://www.w3.org/2001/XMLSchema#string

P2860

Expression of cancer/testis tumor associated antigens in cervical squamous cell carcinoma

Prognostic relevance of MAGE-A4 tumor antigen expression in transitional cell carcinoma of the urinary bladder: a tissue microarray study

Cancer-testis antigen expression in uterine malignancies with an emphasis on carcinosarcomas and papillary serous carcinomas

Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.

Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers.

The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer.

Cancer/testis tumour-associated antigens: immunohistochemical detection with monoclonal antibodies.

Desmoplastic small round cell tumor: current management and recent findings.

P2888

s00428-017-2206-z

P304

383-392

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00428-017-2206-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

471

http://www.w3.org/2001/XMLSchema#string

P50

Takeaki Ishii

P577

2017-07-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28744588

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy